Online resource

Switching to biosimilar SDZ-ADL in patients with moderate-to-severe active rheumatoid arthritis: 48-week efficacy, safety and immunogenicity results from the Phase III, randomized, double-blind ADMYRA study

Piotr Wiland[1*], Sławomir Jeka[2], Eva Dokoupilová[3], Jan Brandt-Jürgens[4], Juan Manuel Miranda Limón[5], Miguel Cantalejo Moreira[6], Raul Veiga Cabello[7], Julia Jauch-Lembach[8], Anjali Thakur[8], Halimuniyazi Haliduola[8], Ines Brueckmann[9] and Norman B. Gaylis[10]

[1]Department of Rheumatology and Internal Medicine, Medical University, Wroclaw, Poland
[2]Department of Rheumatology and Connective Tissue Diseases, University Hospital No. 2, Collegium Medicum UMK, Bydgoszcz, Poland
[3]MEDICAL PLUS s.r.o., Uherske Hradiste; University of Veterinary and Pharmaceutical sciences, Faculty of Pharmacy, Department of Pharmaceutics, Czech Republic
[4]Rheumatology private practice, Berlin, Germany
[5]RM Pharma Specialists, Mexico City, Mexico
[6]Unidad de Reumatología, Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain
[7]Hospital Central de la Defensa, Glorieta Ejército, 1, 28047 Madrid, Spain
[8]Global Clinical Development, Biopharmaceuticals, Hexal AG (A Sandoz Company), Holzkirchen, Germany
[9]Global Medical Affairs, Biopharmaceutical, Hexal AG (A Sandoz Company), Holzkirchen, Germany
[10]Arthritis & Rheumatic Disease Specialties, Aventura, FL, USA

Address for correspondence

Prof. dr hab. Piotr Wiland
Department of Rheumatology and Internal Medicine,
Medical University,
Wroclaw, Poland

Telephone: +48 71 734 33 00
Fax: +48 71 734 33 09
Email: pwiland1@gmail.com

Supplementary Figure S1. Patient disposition



N, total number of patients; ref-ADL- reference adalimumab; SDZ- Sandoz biosimilar
Week 12: primary endpoint assessment; Week 24: end of Study Period 1, patients in the ref-ADL group were switched to SDZ-ADL for the second half of the study; Week 48: end of study

Reasons for Discontinuation in study periods 1 and 2

The proportion of patients who discontinued during Study Period 1 (SP1 FAS) in the SDZ-ADL group and ref-ADL group were 14 (7.9%) and 8 (4.5%), respectively. Main reasons of discontinuation include:

Reason	**SDZ-ADL N=177 n (%)**	**Ref-ADL N=176 n (%)**
Withdrawal by patient	8 (4.5)	4 (2.3)
Protocol deviation(s)	2 (1.1)	1 (0.6)
Adverse event(s)	1 (0.6)	1 (0.6)
Loss to follow-up	1 (0.6)	1 (0.6)
Lack of efficacy	1 (0.6)	0
Other	0	1 (0.6)
Pregnancy	1 (0.6)	0

The proportion of patients who discontinued during Study Period 2 (SP2 FAS) in the SDZ-ADL group and ref-ADL group were14 (8.8%) and 8 (4.8%) respectively. Main reasons of discontinuation include:

Reason	**Continued SDZ-ADL N=159**	**Ref-ADL to SDZ-ADL N=166**
Adverse event(s)	5 (3.1)	0
Lack of efficacy	3 (1.9)	2 (1.2)
Other	3 (1.9)	2 (1.2)
Withdrawal by patient	2 (1.3)	2 (1.2)
Loss to follow-up	0	2 (1.2)
Protocol deviation(s)	1 (0.6)	0

Supplementary Table S1: Mean change from baseline in the assessment scores after the switch from ref-ADL to SDZ-ADL (SP1 FAS)

Time point	SDZ-ADL (N=177)	"ref-ADL/switched SDZ-ADL" (N=176)
Patient's pain assessment score, mean (SD)		
Week 24	-38.5 (25.7)	-41.4 (24.2)
Week 48	-36.0 (27.7)	-39.2 (26.9)
Patient's global assessment of disease activity, mean (SD)		
Week 24	-38.2 (24.1)	-41.5 (23.9)
Week 48	-35.1 (25.7)	-39.4 (25.7)
Physician's global assessment of disease activity, mean (SD)		
Week 24	-46.3 (22.2)	-47.3 (20.6)
Week 48	-44.6 (23.4)	-47.2 (22.1)

ref-ADL, reference adalimumab; SDZ-ADL, Sandoz adalimumab SD, standard deviation

SP1 FAS, study period 1 full analysis set: all randomized patients to whom study drug was administered;

Supplementary Table S2: Change from baseline in DAS28-CRP up to Week 24 (SP1 FAS)

	SDZ-ADL (N=177)		ref-ADL (N=176)	
Visit	**At time point n; Mean (SD)**	**Change from baseline**	**At time point n; Mean (SD)**	**Change from baseline**
Baseline	174; 5.6 (0.88)		175; 5.72 (0.84)	
Week 4	169; 4.2 (1.23)	168; -1.40 (1.06)	172; 4.16 (1.12)	171; -1.55 (1.05)
Week 12	167; 3.5 (1.25)	166; -2.12 (1.17)	168; 3.5 (1.21)	167; -2.24 (1.13)
Week 24	160; 2.9 (1.01)	158; -2.71(1.19)	167; 2.76 (1.0)	166; -2.94 (1.08)

CRP - C-reactive protein, DAS - disease activity score; n - total number of patients assessed; ref-ADL- reference adalimumab; SDZ- Sandoz biosimilar adalimumab

Supplementary Table S3: Proportion of patients achieving EULAR remission, good response, or moderate response up to Week 24 (SP1 FAS)

		SDZ-ADL (N=177)		ref-ADL (N=176)	
Response	**Visit**	**M**	**n (%)**	**M**	**n (%)**
EULAR remission	Week 4	169	19 (11.2)	172	13 (7.6)
	Week 12	167	42 (25.1)	168	43 (25.6)
	Week 24	160	61 (38.1)	167	80 (47.9)
EULAR good response	Week 4	168	32 (19.0)	171	34 (19.9)
	Week 12	166	65 (39.2)	167	70 (41.9)
	Week 24	158	94 (59.5)	166	108 (65.1)
EULAR moderate response	Week 4	168	82 (48.8)	171	94 (55.0)
	Week 12	166	79 (47.6)	167	79 (47.3)
	Week 24	158	54 (34.2)	166	55 (33.1)

EULAR, European League Against Rheumatism; M - total number of patients with evaluable data in each group at a visit; n - total number of patients achieving response/remission; ref-ADL- reference adalimumab; SDZ- Sandoz biosimilar adalimumab; SP1 FAS – study period 1 full analysis set

Supplementary Table S4: Proportion of patients achieving remission according to Boolean definition up to Week 24 (SP1 FAS)

	SDZ-ADL (N=177)		ref-ADL (N=176)	
Visit	**M**	**n (%)**	**M**	**n (%)**
Week 4	169	5 (3.0)	172	1 (0.6)
Week 12	167	13 (7.8)	168	12 (7.1)
Week 24	160	24 (15.0)	167	29 (17.4)

M - total number of patients with evaluable data in each group at a visit; n - total number of patients achieving response/remission (Remission according to Boolean definition is defined as TJC <=1, SJC<=1, CRP<=1 mg/dl and patient global assessment (PtGA)<=1); ref-ADL- reference adalimumab; SDZ- Sandoz biosimilar adalimumab; SP1 FAS – study period 1 full analysis set

Supplementary Table S5: Summary of number of patients achieving ACR20/50/70 response up to Week 24 (SP1 FAS)

		SDZ-ADL (N=177)		ref-ADL (N=176)	
Response	**Visit**	**M**	**n (%)**	**M**	**n (%)**
ACR20 response	Week 4	174	85 (48.9)	173	91 (52.6)
	Week 12	169	119 (70.4)	170	129 (75.9)
	Week 24	164	136 (82.9)	168	156 (92.9)
ACR50 response	Week 4	174	29 (16.7)	173	32 (18.5)
	Week 12	169	62 (36.7)	170	77 (45.3)
	Week 24	164	97 (59.1)	168	113 (67.3)
ACR70 response	Week 4	174	8 (4.6)	173	10 (5.8)
	Week 12	169	29 (17.2)	170	38 (22.4)
	Week 24	164	55 (33.5)	168	63 (37.5)

ACR - American College of Rheumatology; M - total number of patients with evaluable data in each group at a visit; n - total number of patients achieving response; ref-ADL- reference adalimumab; SDZ- Sandoz biosimilar adalimumab; SP1 FAS – study period 1 full analysis set